Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk <i>NPM1</i>-Mutated AML
Onyee Chan(Moffitt Cancer Center), Jeffrey E. Lancet(Cornell University), Gail J. Roboz(Cornell University), Jinming Song(Moffitt Cancer Center), Austin Ellis(Moffitt Cancer Center), David A. Sallman(Moffitt Cancer Center), Somedeb Ball(Vanderbilt University), Eric Padron(Moffitt Cancer Center), Mohammad Hussaini(Moffitt Cancer Center), Andrew Kuykendall(Moffitt Cancer Center), Kendra Sweet(Moffitt Cancer Center), Hammad Tashkandi, Caroline Hana(Moffitt Cancer Center), Najla Al Ali(Moffitt Cancer Center), Yehuda E. Deutsch(Moffitt Cancer Center), Pinkal Desai(NewYork–Presbyterian Hospital), Chetasi Talati(Moffitt Cancer Center), Justin Grenet(Cornell University), Ling Zhang(Moffitt Cancer Center), Rami S. Komrokji(Moffitt Cancer Center), Alison R. Walker(The Ohio State University), Seongseok Yun(Moffitt Cancer Center)
Cited by 2
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k